Coya Therapeutics (COYA) Interest Coverage Ratio: History & Chart

Coya Therapeutics, Inc.(COYA)

Biotechnology · Houston, TX

$4.98+0.13 (+2.68%)

Delayed quote: Oct 6, 2026, 12:24 PM EDT

About Coya Therapeutics, Inc.

Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.

Houston, TX

8 employees

www.coyatherapeutics.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Arun Swaminathan

View full financials

NAME	MARKET CAP	INTEREST COVERAGE RATIO	TTM	3Y	5Y
Coya Therapeutics, Inc. (COYA)	$116.82M	N/A	N/A	N/A	N/A
Genelux Corporation (GNLX)vs ›	$116.14M	N/A	N/A	N/A	N/A
Caribou Biosciences, Inc. (CRBU)vs ›	$117.03M	N/A	N/A	N/A	N/A
Lucid Diagnostics Inc. (LUCD)vs ›	$115.93M	-2256.36x	N/A	N/A	N/A
BGM Group Ltd. (BGM)vs ›	$115.77M	N/A	30.61x	29.12x	24.09x
LENZ Therapeutics, Inc. (LENZ)vs ›	$118.05M	N/A	N/A	N/A	N/A
Foghorn Therapeutics Inc. (FHTX)vs ›	$114.20M	N/A	N/A	N/A	N/A
MaxCyte, Inc. (MXCT)vs ›	$113.01M	N/A	N/A	N/A	N/A
Seer, Inc. (SEER)vs ›	$121.23M	N/A	N/A	N/A	N/A
TuHURA Biosciences, Inc. (HURA)vs ›	$122.27M	-50.85x	N/A	N/A	N/A

NAME

MARKET CAP

INTEREST COVERAGE RATIO

TTM

Coya Therapeutics, Inc. (COYA)

$116.82M

N/A

Genelux Corporation (GNLX)vs ›

$116.14M

N/A

Caribou Biosciences, Inc. (CRBU)vs ›

$117.03M